Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Plus Interferon Alpha vs Octreotide Plus Bevacizumab in Advanced Carcinoid Patients
NCT00569127Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2007
- Primary completion
- Jan 2015
- Modality
- Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab, interferon alfa-2b in Neuroendocrine Neoplasm (NEN), sponsored by National Cancer Institute. Started Dec 2007; status: active, not recruiting.
02
Drugs
bevacizumabinterferon alfa-2b
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00569127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00569127.